Immunic said its FY 2025 net loss was about USD 97.2 million, or USD 0.62 per basic and diluted share, compared with a net loss of about USD 100.5 million a year earlier. FY 2025 R&D expenses were USD 82.0 million and G&A expenses were USD 21.2 million, while interest income was USD 1.0 million and other income (expense) was USD 5.0 million. Cash and cash equivalents totaled about USD 15.5 million as of Dec. 31, 2025; the company also reported about USD 187.0 million in net cash proceeds from a February 2026 private placement, and said it expects to fund operations into late 2027. On business updates, Immunic said top-line data from the Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing multiple sclerosis are expected by end-2026, with a planned U.S. NDA submission in mid-2027 and a targeted potential regulatory approval date in 2028. The company said it plans to initiate a Phase 3 program in primary progressive multiple sclerosis later in 2026, estimated to take about 3.5 to 4 years to complete, and noted it is preparing further clinical testing of IMU-856 contingent on financing, licensing or partnering. Immunic also said it completed an oversubscribed private placement of up to USD 400 million in gross proceeds, including USD 200 million received at closing on Feb. 17, 2026, and announced board and leadership updates including an ongoing search for a new CEO.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2281602_en), on February 26, 2026, and is solely responsible for the information contained therein.
Comments